Allison KH, Wolff AC. ERBB2-low breast cancer-Is it a fact or fiction, and do we have the right assay? JAMA Oncol 2022;8(4):610-1. Abstract

Bardia A et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021;384(16):1529-41. Abstract

Hurvitz SA. DESTINY-changing results for advanced breast cancer. N Engl J Med 2022; 387(1):75-6. Abstract

Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract

Mosele F et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: The phase 2 DAISY trial. Nat Med 2023;29(8):2110-20. Abstract

Moy B et al. Chemotherapy and targeted therapy for human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2022;40(26):3088-90. Abstract

Tarantino P et al. Navigating the HER2-low paradigm in breast oncology: New standards, future horizons. Cancer Discov 2022;12(9):2026-30. Abstract

Wolff AC et al. Human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2023;147(9):993-1000. Abstract

Wolff AC et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 2018;36(20):2105-22. Abstract